Cargando…

Evidence of Maternal Antibodies Elicited by COVID-19 Vaccination in Amniotic Fluid: Report of Two Cases in Italy

With SARS-CoV-2 infection, pregnant women may be at a high risk of severe disease and adverse perinatal outcomes. A COVID-19 vaccination campaign represents the key strategy to combat the pandemic; however, public acceptance of maternal immunization has to be improved, which may be achieved by highl...

Descripción completa

Detalles Bibliográficos
Autores principales: Colavita, Francesca, Oliva, Alessandra, Bettini, Aurora, Antinori, Andrea, Girardi, Enrico, Castilletti, Concetta, Vaia, Francesco, Liuzzi, Giuseppina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321354/
https://www.ncbi.nlm.nih.gov/pubmed/35891572
http://dx.doi.org/10.3390/v14071592
_version_ 1784756024661508096
author Colavita, Francesca
Oliva, Alessandra
Bettini, Aurora
Antinori, Andrea
Girardi, Enrico
Castilletti, Concetta
Vaia, Francesco
Liuzzi, Giuseppina
author_facet Colavita, Francesca
Oliva, Alessandra
Bettini, Aurora
Antinori, Andrea
Girardi, Enrico
Castilletti, Concetta
Vaia, Francesco
Liuzzi, Giuseppina
author_sort Colavita, Francesca
collection PubMed
description With SARS-CoV-2 infection, pregnant women may be at a high risk of severe disease and adverse perinatal outcomes. A COVID-19 vaccination campaign represents the key strategy to combat the pandemic; however, public acceptance of maternal immunization has to be improved, which may be achieved by highlighting the promising mechanism of passive immunity as a strategy for protecting newborns against SARS-CoV-2 infection. We tested the anti-SARS-CoV-2 antibody response following COVID-19 full-dose vaccination in the serum and amniotic fluid of two pregnant women who presented between April and June 2021, at the Center for the Treatment and Prevention of Infections in Pregnancy of the National Institute for Infectious Diseases “L. Spallanzani”, for antenatal consultancy. Anti-SARS-CoV-2 IgG was found in residual samples of amniotic fluid collected from both women at the 18th week of gestation (63 and 131 days after the second dose’s administration). Titers in amniotic fluid mirrored the levels detected in serum and were inversely linked to the time from vaccination. Our results suggest that antibodies elicited by COVID-19 vaccination can cross the placenta and reach the fetus; therefore, they may offer passive immunity at birth. It is critical to fully understand the kinetics of the maternal response to vaccination, the efficiency of IgG transfer, and the persistence of antibodies in infants to optimize maternal immunization regimens.
format Online
Article
Text
id pubmed-9321354
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93213542022-07-27 Evidence of Maternal Antibodies Elicited by COVID-19 Vaccination in Amniotic Fluid: Report of Two Cases in Italy Colavita, Francesca Oliva, Alessandra Bettini, Aurora Antinori, Andrea Girardi, Enrico Castilletti, Concetta Vaia, Francesco Liuzzi, Giuseppina Viruses Case Report With SARS-CoV-2 infection, pregnant women may be at a high risk of severe disease and adverse perinatal outcomes. A COVID-19 vaccination campaign represents the key strategy to combat the pandemic; however, public acceptance of maternal immunization has to be improved, which may be achieved by highlighting the promising mechanism of passive immunity as a strategy for protecting newborns against SARS-CoV-2 infection. We tested the anti-SARS-CoV-2 antibody response following COVID-19 full-dose vaccination in the serum and amniotic fluid of two pregnant women who presented between April and June 2021, at the Center for the Treatment and Prevention of Infections in Pregnancy of the National Institute for Infectious Diseases “L. Spallanzani”, for antenatal consultancy. Anti-SARS-CoV-2 IgG was found in residual samples of amniotic fluid collected from both women at the 18th week of gestation (63 and 131 days after the second dose’s administration). Titers in amniotic fluid mirrored the levels detected in serum and were inversely linked to the time from vaccination. Our results suggest that antibodies elicited by COVID-19 vaccination can cross the placenta and reach the fetus; therefore, they may offer passive immunity at birth. It is critical to fully understand the kinetics of the maternal response to vaccination, the efficiency of IgG transfer, and the persistence of antibodies in infants to optimize maternal immunization regimens. MDPI 2022-07-21 /pmc/articles/PMC9321354/ /pubmed/35891572 http://dx.doi.org/10.3390/v14071592 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Colavita, Francesca
Oliva, Alessandra
Bettini, Aurora
Antinori, Andrea
Girardi, Enrico
Castilletti, Concetta
Vaia, Francesco
Liuzzi, Giuseppina
Evidence of Maternal Antibodies Elicited by COVID-19 Vaccination in Amniotic Fluid: Report of Two Cases in Italy
title Evidence of Maternal Antibodies Elicited by COVID-19 Vaccination in Amniotic Fluid: Report of Two Cases in Italy
title_full Evidence of Maternal Antibodies Elicited by COVID-19 Vaccination in Amniotic Fluid: Report of Two Cases in Italy
title_fullStr Evidence of Maternal Antibodies Elicited by COVID-19 Vaccination in Amniotic Fluid: Report of Two Cases in Italy
title_full_unstemmed Evidence of Maternal Antibodies Elicited by COVID-19 Vaccination in Amniotic Fluid: Report of Two Cases in Italy
title_short Evidence of Maternal Antibodies Elicited by COVID-19 Vaccination in Amniotic Fluid: Report of Two Cases in Italy
title_sort evidence of maternal antibodies elicited by covid-19 vaccination in amniotic fluid: report of two cases in italy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321354/
https://www.ncbi.nlm.nih.gov/pubmed/35891572
http://dx.doi.org/10.3390/v14071592
work_keys_str_mv AT colavitafrancesca evidenceofmaternalantibodieselicitedbycovid19vaccinationinamnioticfluidreportoftwocasesinitaly
AT olivaalessandra evidenceofmaternalantibodieselicitedbycovid19vaccinationinamnioticfluidreportoftwocasesinitaly
AT bettiniaurora evidenceofmaternalantibodieselicitedbycovid19vaccinationinamnioticfluidreportoftwocasesinitaly
AT antinoriandrea evidenceofmaternalantibodieselicitedbycovid19vaccinationinamnioticfluidreportoftwocasesinitaly
AT girardienrico evidenceofmaternalantibodieselicitedbycovid19vaccinationinamnioticfluidreportoftwocasesinitaly
AT castilletticoncetta evidenceofmaternalantibodieselicitedbycovid19vaccinationinamnioticfluidreportoftwocasesinitaly
AT vaiafrancesco evidenceofmaternalantibodieselicitedbycovid19vaccinationinamnioticfluidreportoftwocasesinitaly
AT liuzzigiuseppina evidenceofmaternalantibodieselicitedbycovid19vaccinationinamnioticfluidreportoftwocasesinitaly